Login / Signup

Reduction in caffeine withdrawal after open-label decaffeinated coffee.

Llewellyn MillsJessica C LeeRobert A BoakesBen Colagiuri
Published in: Journal of psychopharmacology (Oxford, England) (2023)
It appears as if open-label placebo caffeine (i.e. decaf) can reduce caffeine withdrawal symptoms, even when people do not hold a conscious expectancy it will do so. There may be ways to integrate open-label placebo procedures into clinical interventions for drug dependence without violating informed consent.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • clinical trial
  • phase ii study
  • study protocol
  • double blind
  • squamous cell carcinoma
  • emergency department
  • depressive symptoms
  • rectal cancer
  • electronic health record